经济观察网博拓生物股价在2026年2月13日出现上涨，可能与公司近期披露的业绩预告及对未来发展的 积极展望有关。 公司在脑机接口领域的战略布局也受到市场关注。根据证券时报网2026年1月25日的报道，公司正通过 旗下产投平台深度参与脑机接口产业，并已战略入股相关企业，试图打造第二增长曲线。 股票近期走势 截至2026年2月13日11:19更新行情数据显示，博拓生物股价当日上涨5.36%，而所属的医疗器械板块指 数当日下跌0.18%，显示其走势显著强于板块整体表现。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 公司于2026年1月23日发布的2025年度业绩预告显示，尽管预计全年归母净利润同比出现较大幅度下 滑，但管理层在后续的投资者交流活动中明确表示，随着中美关税环境趋于稳定，以及公司差异化竞争 产品在多个市场陆续获证，对2026年营业收入实现稳步增长抱有信心。这种"短期业绩承压，但未来增 长拐点可期"的预期可能对市场情绪产生了积极影响。 战略推进 ...

据中国证监会2月6日消息，又有两家上市公司被中国证监会立案。1月7日，深圳市亚辉龙生物科技 股份有限公司（以下简称"亚辉龙"）披露签署战略合作框架协议的公告，涉嫌误导性陈述。相较于亚辉 龙因蹭热点而涉嫌误导性陈述被立案，常州天晟新材料集团有限公司（以下简称"天晟新材"）的涉嫌违 规事项则指向历史财务信息披露。近日，中国证监会已对两家公司立案调查。下一步，将在全面调查的 基础上依法处理，切实维护市场健康发展。 2月6日晚，亚辉龙和天晟新材相继发布公告称，公司已于2026年2月6日收到中国证监会下发的《立 案告知书》，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。 亚辉龙蹭"脑机接口"热点 亚辉龙的立案调查与近期市场热点"脑机接口"相关公告的误导性陈述密切相关。此前，在"脑机接 口"热潮之下，亚辉龙因信披"蹭热点"被上海证券交易所监管警示。 1月6日晚间，亚辉龙发布《关于自愿披露签署战略合作框架协议的公告》。根据公告，亚辉龙宣布 与深圳脑机星链科技有限公司（以下简称"脑机星链"）签署战略合作框架协议，共同达成战略合作，通 过整合脑机接口技术、临床与市场资源，共同开发脑机接口相关在研产品，并推进后续市场拓展 ...

Core Viewpoint - The establishment of the "Brain-Computer Interface and Big Health Joint Laboratory" between Dineike and the University of Science and Technology of China aims to enhance research and development in brain signal processing and analysis, contributing to the "Healthy China" initiative through innovative technology [1] Group 1 - The joint laboratory was officially inaugurated on January 27, 2026, at the Future Center of the University of Science and Technology of China [1] - The collaboration will focus on developing more accurate and intelligent algorithm models for brain signal processing [1] - Key figures present at the inauguration included Professor Chen Xun, Vice President of the Advanced Technology Research Institute, and Mr. Miao Guodong, Chairman of Dineike [1] Group 2 - The partnership aims to drive technological breakthroughs and product transformation in specific application scenarios related to brain-computer interface technology [1] - This initiative is positioned to inject new technological momentum into the construction of a "Healthy China" [1]

Core Viewpoint - The National Bureau of Statistics summarized the economic performance of 2025 with the terms "stable, progressive, new, and resilient," reflecting the strong foundation, multiple advantages, resilience, and potential of the Chinese economy [1]. Group 1: Economic Stability - The average urban survey unemployment rate is 5.2%, indicating overall stable employment [3]. - The total goods trade reached a new high, with foreign exchange reserves exceeding 3.3 trillion yuan, showcasing the resilience of the economy amidst various risks and challenges [3]. Group 2: Economic Growth Contributions - The added value of high-tech manufacturing industries accounted for 17.1% of the total industrial added value, with final consumption expenditure contributing over 50% to economic growth [4]. - The actual growth of per capita disposable income for residents was 5.0%, aligning with economic growth [4]. Group 3: Innovation and R&D - R&D expenditure intensity reached 2.8%, surpassing the OECD average for the first time [5]. - China entered the global top ten in the innovation index, with significant achievements in cutting-edge fields such as artificial intelligence, quantum technology, and brain-machine interfaces [5]. Group 4: Green Economy Development - The green economy, including green electricity and energy, is thriving, with new energy vehicle sales accounting for over 50% of domestic new car sales [6].

Core Viewpoint - The recent share reduction plan by a significant shareholder of Weisi Medical raises concerns about the company's current performance and future prospects in the brain-computer interface sector, especially as the company has not yet achieved substantial revenue from its related products [1] Group 1: Shareholder Actions - The shareholder Nanjing Zhida Venture Capital Center plans to reduce its stake in Weisi Medical by up to 2,873,137 shares, which is no more than 3% of the total share capital [1] - Currently, Zhida Venture Capital holds 7.06% of Weisi Medical's shares [1] - This shareholder has previously cashed out over 52 million yuan in the second half of last year [1] Group 2: Business Performance - Weisi Medical's new products in the brain-computer interface field are still in the early stages of market cultivation as of the end of 2025 [1] - The company is primarily focusing on non-invasive technology, which significantly differs from the invasive brain-computer interfaces that are currently leading internationally [1] - The related products have not yet achieved large-scale sales, contributing only a limited amount to the overall revenue [1]

Core Viewpoint - The major shareholder of Xiangyu Medical has announced a plan to reduce its stake, which raises questions among investors about the company's optimistic outlook on its brain-computer interface products and business prospects [1] Group 1: Shareholder Actions - The controlling shareholder's action, An'yang Qixu Trade Consulting Service Center, plans to reduce its holdings by up to 3% of the total share capital between February 4, 2026, and May 3, 2026 [1] - This reduction comes after a significant increase in the company's stock price, driven by enthusiasm in the brain-computer interface sector [1] Group 2: Market Reactions - Investors have expressed skepticism on social media regarding the decision to reduce holdings, questioning the rationale behind the sell-off given the company's previous optimistic statements about its brain-computer interface products [1] - The company appeared optimistic during discussions with various institutions regarding its brain-computer interface-related products and business outlook [1]

Core Viewpoint - The surge in Xiangyu Medical's stock price is driven by the excitement surrounding the "brain-computer interface" concept, despite concerns over a major shareholder's plan to reduce their stake and the company's declining net profits [1][2][3]. Group 1: Stock Performance - Xiangyu Medical's stock price increased significantly at the beginning of 2026, with a maximum rise of 57% over three trading days, reaching a high of 95 yuan, marking a cumulative increase of over 300% from its low in 2024 [1][2]. - The stock's performance triggered an abnormal trading situation, with the stock price deviating by 30% over three consecutive trading days [3]. Group 2: Shareholder Actions - On January 13, 2026, Xiangyu Medical announced that its major shareholder, Anyang Qixu Trade Consulting Service Center, planned to reduce its stake by no more than 3% between February 4 and May 3, 2026 [1]. - The reduction plan raised questions among investors, especially given the recent stock price surge [4]. Group 3: Company Outlook and Strategy - Xiangyu Medical remains optimistic about its future, focusing on non-invasive brain-computer interface technology and planning to launch several new products in 2026, aiming to expand its presence in over 1,000 top-tier hospitals [2][4]. - The company has invested significantly in research and development, with R&D expenses increasing by 42% in 2024 and 20.19% in the first three quarters of 2025 [6]. Group 4: Financial Performance - Despite the stock price increase, Xiangyu Medical's net profit has been declining, with a 54.68% drop in 2024 and a 40.09% decrease in the first three quarters of 2025 [5][6]. - The company attributes the decline in net profit to increased R&D investments and challenges in the economic environment affecting revenue [6].

Core Viewpoint - The company YHLO (688575.SH) received a regulatory warning for misleading information disclosure related to its strategic cooperation with Shenzhen Brain Machine Star Chain Technology Co., Ltd. regarding brain-computer interface technology [2][5]. Group 1: Regulatory Issues - YHLO's announcement about the cooperation with Brain Machine Star Chain contained inconsistent statements regarding the technical approach, failing to adequately disclose risks related to collaboration feasibility and uncertainty [2]. - The Shanghai Stock Exchange issued an inquiry letter shortly after YHLO's announcement, leading to a regulatory warning for the company's then Secretary of the Board, Wang Mingyang [2]. Group 2: Company Background and Product Development - Brain Machine Star Chain was established in September 2025 with a registered capital of 5 million yuan, and its products have not yet obtained medical device registration certificates, leading to uncertainty about their approval timeline [2]. - YHLO stated that the cooperation would not have a significant impact on its business, and the development cycle for related projects is long and uncertain [2][5]. Group 3: Stock Price Movement - On January 6, YHLO's stock price rose by 6.52%, with trading volume increasing by 299% before the announcement of the strategic cooperation [4]. - Following the regulatory inquiry and a supplementary announcement, YHLO's stock price stabilized at 15.53 yuan per share by January 7, remaining unchanged from the previous closing price [6]. Group 4: Financial Performance - YHLO reported a revenue of approximately 1.287 billion yuan for the first nine months of 2025, a year-on-year decline of 7.69%, with net profit dropping by 72.36% due to reduced domestic market demand and losses from financial assets [7]. - The company plans to invest no more than 15 million yuan in Brain Machine Star Chain, which is a small proportion of its cash reserves of 466 million yuan as of September 2025 [8].

Core Viewpoint - Qiangnao Technology has submitted a confidential IPO application for the Hong Kong stock market, potentially raising hundreds of millions of dollars, and is expected to be the first company listed among the "Six Little Dragons of Hangzhou" [1] Company Overview - Qiangnao Technology is recognized as the first unicorn in the brain-computer interface sector in China, focusing on breakthroughs in underlying technologies for brain-computer interfaces [1] - The company aims to establish a communication pathway between the brain and external devices to facilitate information exchange, providing solutions for rehabilitation of disabled individuals and addressing brain diseases such as autism [1] - Several products have already been launched by Qiangnao Technology in the market [1] IPO Details - The IPO is being conducted in collaboration with China International Capital Corporation (CICC) and UBS Group [1] - The fundraising target for this IPO is expected to be in the range of several hundred million dollars [1]

Group 1 - The core viewpoint of the news is that Neural Regeneration Technology (RGC.US) has seen a significant stock price increase, rising 16.3% in pre-market trading and a total of 157% over the past three days, driven by Elon Musk's recent production forecast, which has catalyzed a surge in the brain-computer interface sector [1] - RGC's relationship with brain-computer interfaces can be understood as an upstream and downstream connection in medicine, where "repairing hardware" relates to "establishing connections" [1] - According to a report from Changjiang Securities, the brain-computer interface industry in China is experiencing rapid advancements, and with policy support, it is expected to enter a period of development opportunities, accelerating the transition from industrial research to commercialization [1] Group 2 - As of January 7, the closing price of RGC was $52.880, reflecting a 60.10% increase, while the pre-market price on January 8 was $61.500, up 16.30% [2] - The stock has shown significant volatility, with a trading range of 59.37% and a turnover rate of 17.48% [2] - The total market capitalization of RGC is approximately $26.149 billion, with a total share count of 494 million [2]